{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06162221",
            "orgStudyIdInfo": {
                "id": "RMC-LUNG-101"
            },
            "organization": {
                "fullName": "Revolution Medicines, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of RAS(ON) Inhibitor Combinations in Patients With Advanced RAS-mutated NSCLC",
            "officialTitle": "A Platform Study of RAS(ON) Inhibitor Combinations in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "study-of-ras-on-inhibitor-combinations-in-patients-with-advanced-ras-mutated-nsclc"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-01-18",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-06",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-11-30",
            "studyFirstSubmitQcDate": "2023-11-30",
            "studyFirstPostDateStruct": {
                "date": "2023-12-08",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-24",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-26",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Revolution Medicines, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with each other.\n\nThe first two subprotocols include the following:\n\nSubprotocol A: RMC-6291 + SOC Subprotocol B: RMC-6236 + SOC",
            "detailedDescription": "The platform study design allows combinations of RAS(ON) inhibitors with other anticancer agents to be evaluated in patients with RAS-mutated solid tumors with a focus on NSCLC.\n\nThis is an open-label platform Phase 1b/2 study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard of Care (SOC), and to define the Recommended Phase 2 Dose and Schedule (RP2DS). Enrollment of patients with KRAS or RAS mutations will be specified in each subprotocol.\n\nSubprotocol A is an open-label, multicenter, Phase 1b/2 study of RMC-6291 in combination with pembrolizumab, with or without chemotherapy, in patients with KRAS G12C-mutated advanced solid tumors.\n\nSubprotocol B is an open-label, multicenter, Phase1b/2 study of RMC-6236 in combination with pembrolizumab, with or without chemotherapy, in patients with RAS-mutated non-small cell lung cancer (NSCLC)\n\nEach subprotocol consists of two parts: Part 1 - Dose Exploration and Part 2 - Dose Expansion."
        },
        "conditionsModule": {
            "conditions": [
                "Non-Small Cell Lung Cancer, NSCLC",
                "KRAS, NRAS, HRAS-mutated NSCLC",
                "KRAS G12C-mutated Solid Tumors, Lung Cancer",
                "Lung Cancer Stage IV, Advanced Solid Tumor, Cancer"
            ],
            "keywords": [
                "NSCLC",
                "KRAS G12C",
                "RAS Mutation",
                "KRAS G12X",
                "Non-Small Cell Lung Cancer",
                "Lung Cancer",
                "Lung Cancer Stage IV",
                "Advanced Solid Tumor",
                "Cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 352,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Subprotocol A: KRAS G12C-Mutated Solid Tumors",
                    "type": "EXPERIMENTAL",
                    "description": "RMC-6291 (BID) and Pembrolizumab (Q3W) with or without Chemotherapy (Q3W-Q4W)",
                    "interventionNames": [
                        "Drug: RMC-6291",
                        "Drug: Pembrolizumab",
                        "Drug: Cisplatin",
                        "Drug: Carboplatin",
                        "Drug: Pemetrexed"
                    ]
                },
                {
                    "label": "Subprotocol B: RAS-mutated NSCLC",
                    "type": "EXPERIMENTAL",
                    "description": "RMC-6236 (QD) and Pembrolizumab (Q3W) with or without Chemotherapy (Q3W-Q4W)",
                    "interventionNames": [
                        "Drug: RMC-6236",
                        "Drug: Pembrolizumab",
                        "Drug: Cisplatin",
                        "Drug: Carboplatin",
                        "Drug: Pemetrexed"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "RMC-6291",
                    "description": "Oral tablet",
                    "armGroupLabels": [
                        "Subprotocol A: KRAS G12C-Mutated Solid Tumors"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "RMC-6236",
                    "description": "Oral tablet",
                    "armGroupLabels": [
                        "Subprotocol B: RAS-mutated NSCLC"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Pembrolizumab",
                    "description": "IV Infusion",
                    "armGroupLabels": [
                        "Subprotocol A: KRAS G12C-Mutated Solid Tumors",
                        "Subprotocol B: RAS-mutated NSCLC"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cisplatin",
                    "description": "IV Infusion",
                    "armGroupLabels": [
                        "Subprotocol A: KRAS G12C-Mutated Solid Tumors",
                        "Subprotocol B: RAS-mutated NSCLC"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Carboplatin",
                    "description": "IV Infusion",
                    "armGroupLabels": [
                        "Subprotocol A: KRAS G12C-Mutated Solid Tumors",
                        "Subprotocol B: RAS-mutated NSCLC"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Pemetrexed",
                    "description": "IV infusion",
                    "armGroupLabels": [
                        "Subprotocol A: KRAS G12C-Mutated Solid Tumors",
                        "Subprotocol B: RAS-mutated NSCLC"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Adverse events",
                    "description": "Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs and clinically significant changes in laboratory values, ECGs and vital signs",
                    "timeFrame": "Up to 5 years"
                },
                {
                    "measure": "Dose limiting toxicities",
                    "description": "Number of participants with dose limiting toxicities",
                    "timeFrame": "21 days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Cmax",
                    "description": "Maximum observed blood concentration of each drug per subprotocol",
                    "timeFrame": "Up to 21 weeks"
                },
                {
                    "measure": "Tmax",
                    "description": "Time to reach maximum blood concentration of each drug per subprotocol",
                    "timeFrame": "Up to 21 weeks"
                },
                {
                    "measure": "AUC",
                    "description": "Area under the concentration-time curve of each drug per subprotocol",
                    "timeFrame": "Up to 21 weeks"
                },
                {
                    "measure": "ORR",
                    "description": "Overall Response Rate per RECIST v1.1",
                    "timeFrame": "Up to 5 years"
                },
                {
                    "measure": "DOR",
                    "description": "Duration of Response per RECIST v1.1",
                    "timeFrame": "Up to 5 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion criteria:\n\nAll Patients (unless otherwise noted):\n\n* \u2265 18 years of age\n* ECOG PS is 0 to 1\n* Adequate organ function as outlined by the study\n* Received prior standard therapy appropriate for tumor type and stage\n* Must have pathologically documented, locally advanced or metastatic KRAS G12C-mutated solid tumor malignancy (not amenable to curative surgery) (Subprotocol A)\n* Must have pathologically documented, locally advanced or metastatic RAS-mutated NSCLC (Subprotocol B)\n\nExclusion criteria:\n\nAll Patients:\n\n* Primary central nervous system (CNS) tumors\n* Impaired gastrointestinal (GI) function that may significantly alter the absorption of RMC drugs\n* Major surgery \\< 28 days of first dose\n* Active or history of interstitial lung disease (ILD) or pneumonitis requiring steroids\n\nOther inclusion/exclusion criteria may apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Revolution Medicines",
                    "role": "CONTACT",
                    "phone": "(650)779-2300",
                    "email": "CT-inquiries@RevMed.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Revolution Medicines",
                    "affiliation": "Revolution Medicines",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "City of Hope - Lennar",
                    "status": "RECRUITING",
                    "city": "Irvine",
                    "state": "California",
                    "zip": "92618",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.66946,
                        "lon": -117.82311
                    }
                },
                {
                    "facility": "Boca Raton Clinical Research Associates",
                    "status": "RECRUITING",
                    "city": "Plantation",
                    "state": "Florida",
                    "zip": "33322",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 26.13421,
                        "lon": -80.23184
                    }
                },
                {
                    "facility": "Clinical Research Alliance",
                    "status": "RECRUITING",
                    "city": "Westbury",
                    "state": "New York",
                    "zip": "11590",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.75566,
                        "lon": -73.58763
                    }
                },
                {
                    "facility": "MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "NEXT Oncology Dallas",
                    "status": "RECRUITING",
                    "city": "Irving",
                    "state": "Texas",
                    "zip": "75039",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.81402,
                        "lon": -96.94889
                    }
                },
                {
                    "facility": "NEXT Oncology Virginia",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                },
                {
                    "facility": "Hospices Civils de Lyon - H\u00f4pital Louis Pradel",
                    "status": "RECRUITING",
                    "city": "Bron",
                    "state": "Auvergne-Rh\u00f4ne-Alpes",
                    "zip": "69500",
                    "country": "France",
                    "geoPoint": {
                        "lat": 45.73333,
                        "lon": 4.91667
                    }
                },
                {
                    "facility": "CHU de Lille Institut C\u0153ur Poumon",
                    "status": "RECRUITING",
                    "city": "Lille",
                    "state": "Hauts-de-France",
                    "zip": "59037",
                    "country": "France",
                    "geoPoint": {
                        "lat": 50.63297,
                        "lon": 3.05858
                    }
                },
                {
                    "facility": "CHU de Nantes",
                    "status": "RECRUITING",
                    "city": "Nantes",
                    "state": "Hauts-de-France",
                    "zip": "44093",
                    "country": "France",
                    "geoPoint": {
                        "lat": 47.21725,
                        "lon": -1.55336
                    }
                },
                {
                    "facility": "Hospital Universitario 12 de Octubre",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "state": "Comunidad De Madrid",
                    "zip": "28041",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008175",
                    "term": "Lung Neoplasms"
                },
                {
                    "id": "D000002289",
                    "term": "Carcinoma, Non-Small-Cell Lung"
                }
            ],
            "ancestors": [
                {
                    "id": "D000012142",
                    "term": "Respiratory Tract Neoplasms"
                },
                {
                    "id": "D000013899",
                    "term": "Thoracic Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                },
                {
                    "id": "D000002283",
                    "term": "Carcinoma, Bronchogenic"
                },
                {
                    "id": "D000001984",
                    "term": "Bronchial Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "asFound": "Non-small Cell Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "asFound": "Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M14979",
                    "name": "Respiratory Tract Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16658",
                    "name": "Thoracic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5540",
                    "name": "Carcinoma, Bronchogenic",
                    "relevance": "LOW"
                },
                {
                    "id": "M5260",
                    "name": "Bronchial Neoplasms",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000016190",
                    "term": "Carboplatin"
                },
                {
                    "id": "C000582435",
                    "term": "Pembrolizumab"
                },
                {
                    "id": "D000068437",
                    "term": "Pemetrexed"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000005493",
                    "term": "Folic Acid Antagonists"
                },
                {
                    "id": "D000019384",
                    "term": "Nucleic Acid Synthesis Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M18650",
                    "name": "Carboplatin",
                    "asFound": "System",
                    "relevance": "HIGH"
                },
                {
                    "id": "M349416",
                    "name": "Pembrolizumab",
                    "asFound": "Mg/m2",
                    "relevance": "HIGH"
                },
                {
                    "id": "M264",
                    "name": "Pemetrexed",
                    "asFound": "Target",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6182",
                    "name": "Cisplatin",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M17546",
                    "name": "Vitamin B Complex",
                    "relevance": "LOW"
                },
                {
                    "id": "M8618",
                    "name": "Folic Acid",
                    "relevance": "LOW"
                },
                {
                    "id": "M8619",
                    "name": "Folic Acid Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "T446",
                    "name": "Folic Acid",
                    "relevance": "LOW"
                },
                {
                    "id": "T447",
                    "name": "Folinic Acid",
                    "relevance": "LOW"
                },
                {
                    "id": "T448",
                    "name": "Folate",
                    "relevance": "LOW"
                },
                {
                    "id": "T475",
                    "name": "Vitamin B9",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Micro",
                    "name": "Micronutrients"
                },
                {
                    "abbrev": "Hemat",
                    "name": "Hematinics"
                },
                {
                    "abbrev": "Vi",
                    "name": "Vitamins"
                }
            ]
        }
    },
    "hasResults": false
}